After Vaccines Row, Sanofi Invests In France, Macron To Secure Supplies
CEO Restates Commitment To France
Executive Summary
Sanofi’s €610m investment helps row to be forgotten – though Macron will ‘place bets’ on several COVID-19 vaccines, not just France’s homegrown candidate.
You may also be interested in...
Sanofi’s Triomphe On Vaccine Plants Of The Future, Regulatory Speed
Sanofi's executive vice-president and head of vaccines, Thomas Triomphe, outlines in an interview with Scrip the role of evolutive vaccine facilities that are adaptable to new platforms like mRNA, a core cog expected to drive the French group’s innovation ambitions. Finding a sustainable ‘sweet spot’ when it comes to regulatory speed post the pandemic is among the other topics the executive touched upon.
Sanofi Confirms Up To 1,680 Job Losses In Europe
The layoffs are part of its bid to cut costs outlined in December.
Sanofi Bets Big On mRNA Vaccines With Expanded Translate Pact
Sanofi and Translate Bio, which hope to advance their mRNA vaccine candidate into a first-in-human clinical trial in the fourth quarter of 2020, have significantly extended their collaboration in that field, with the French giant plonking down a whopping $425m upfront fee.